Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254441 | 1.00 | TP53 (0.49) | TP53KMT2AMEN1NOTUMLMNA | |
| SCHEMBL5934873 | 0.86 | NOTUM (0.57) | KMT2AMEN1NOTUMLMNAGRM5 | |
| Hydrochloric Acid SCHEMBL6006151 | 0.84 | NOTUM (0.55) | KMT2AMEN1NOTUMLMNAGRM5 | |
| SCHEMBL14964128 | 0.82 | MAPT (0.49) | TP53KMT2AMEN1NOTUMLMNA | |
| SCHEMBL873113 | 0.82 | MAPT (0.53) | TP53KMT2AMEN1NOTUMLMNA | |
| SCHEMBL29635591 | 0.78 | NOTUM (0.63) | NOTUMLMNAMAPTALDH1A1KDM4E | |
| SCHEMBL254803 | 0.78 | NOTUM (0.63) | NOTUMLMNAMAPTALDH1A1KDM4E | |
| SCHEMBL82721 | 0.78 | NOTUM (0.64) | TP53KMT2AMEN1NOTUMGRM5 | |
| SCHEMBL14960622 | 0.77 | ERCC1 (0.46) | TP53KMT2AMEN1NOTUMLMNA | |
| SCHEMBL2463180 | 0.77 | NOTUM (0.48) | KMT2AMEN1NOTUMLMNAGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | claimed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-28 | — | — | US | disclosed |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | TP53 4857/4885KMT2A 659/4885MEN1 438/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | TP53 4867/4885KMT2A 912/4885MEN1 491/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | TP53 4868/4885KMT2A 908/4885MEN1 473/4885 |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | NAMPT, NADK, NNT | TP53 595/4885KMT2A 727/4885MEN1 329/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | TP53 4877/4885KMT2A 1615/4885MEN1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.